Clinical Trials Logo

Glaucoma clinical trials

View clinical trials related to Glaucoma.

Filter by:

NCT ID: NCT03108443 Active, not recruiting - Glaucoma Clinical Trials

Novel Markers for Detecting Early Progression of Glaucoma

Start date: April 1, 2018
Phase:
Study type: Observational

Current methods of detecting glaucoma and monitoring its progression over time involve visual assessment of the optic nerve, thickness measurements of nerve tissue in the eye (using optical coherence tomography, OCT) as well as functional tests which measure peripheral, or side, vision. The objective of this study is to determine if a new technique of measuring blood flow in the eye, using OCT, can be used to better detect and/or monitor changes in glaucoma patients and suspects than these methods.

NCT ID: NCT03077789 Active, not recruiting - Congenital Glaucoma Clinical Trials

Prospective Study of the Diagnostic and Therapeutic Management of Congenital Glaucoma in France

Conglau
Start date: April 2013
Phase: N/A
Study type: Interventional

Evidence of a relationship between age at discovery of congenital glaucoma and visual acuity at 4 years of age. The delay in diagnosis is a factor of poor visual acuity. Will justify the implementation of information programs with health and education professionals in order to improve the functional prognosis of patients with congenital glaucoma.

NCT ID: NCT02901730 Active, not recruiting - Glaucoma Clinical Trials

Clinical Study of LPI With Different Laser Wavelengths

Start date: September 2016
Phase: N/A
Study type: Interventional

Glaucoma is the second cause of blindness worldwide. Laser peripheral iridoplasty (LPI) is a simple and effective treatment for angle closure glaucoma. LPI can widen or reopen an existing angle close or angle adhesion in order to reduce the risk of attack of the angle closure glaucoma. However, there are very little research on the laser site, laser wavelengths, laser energy and laser spot intervals. The purpose of this study is to determine the optimum laser wavelengths of LPI.

NCT ID: NCT02870504 Active, not recruiting - Glaucoma Clinical Trials

Clinical Study of LPI on Different Sites of Iris

Start date: July 2016
Phase: N/A
Study type: Interventional

Glaucoma is the second cause of blindness worldwide. Laser peripheral iridoplasty (LPI) is a simple and effective treatment for angle closure glaucoma. LPI can widen or reopen an existing angle close or angle adhesion in order to reduce the risk of attack of the angle closure glaucoma. However, there are very little research on the laser site, laser wavelengths, laser energy and laser spot intervals. The purpose of this study is to determine the optimum laser site of LPI.

NCT ID: NCT02867527 Active, not recruiting - Glaucoma Clinical Trials

Prospective Constitution of Database Gathering Data of Patients Suffering From Glaucoma Followed at University Hospital of Grenoble

BDD_GLAUCOME
Start date: January 2014
Phase:
Study type: Observational [Patient Registry]

Few publications provide information on the natural history of glaucoma, outside of clinical trials do not always reflect what is observed in common situation for various reasons (specific selection criteria and sometimes restrictive, stronger motivations patients and physicians to comply with follow-up visits and prescribed treatments, etc.). Therefore, much information on the natural history of glaucoma are unknown to date (degradation rate of visual field and visual function over time, risk of blindness in the years following diagnosis, effects of various treatments to reduce intraocular pressure and preserving visual field deterioration, etc.). Obtaining such important data to improve the management of glaucoma patients (choice of treatment methods, identification of predictors of rapid change that can make choosing more aggressive treatment and more regular monitoring, etc.) requires the establishment of cohort of patients followed and treated with the methods usually used in current practice, and besides therapeutic trial.

NCT ID: NCT02862938 Active, not recruiting - Glaucoma Clinical Trials

Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration

Start date: June 2016
Phase: Phase 2
Study type: Interventional

This is a randomized, sham controlled, masked clinical trial of 60 study participants with glaucoma. Participants with a qualifying study eye will be randomized after screening and baseline evaluations to receive the NT-501 encapsulated cell therapy (ECT) implant or a sham surgery (control arm), and no explant will be required. An examination for safety will occur one day and one week following implant and periodically thereafter for 24 months post-implant. Based on the primary analysis of data at 6 months, patients in the control arm may be offered the NT-501 ECT implant at the 12 month time point.

NCT ID: NCT02825264 Active, not recruiting - Open Angle Glaucoma Clinical Trials

STAR-LIFE Registry: STARflo Glaucoma Implant Clinical Experience Program

Start date: July 2016
Phase:
Study type: Observational

STARflo is a novel suprachoroidal Glaucoma Drainage Device (GDD), bleb-free, exhibiting anti-fibrotic properties. Release of this CE Marked implant has been limited to leading Glaucoma Centers in Europe.

NCT ID: NCT02772666 Active, not recruiting - Multiple Sclerosis Clinical Trials

Novel Portable Diagnostic Device for Automatic Detection of Relative Afferent Pupillary Defect

Start date: December 2015
Phase: N/A
Study type: Observational

This study is to evaluate the ability of a newly designed device, Optic Nerve Glass (O-Glass) to detect relative afferent pupillary defect (RAPD). In this prospective observational study, 44 patients (diagnosed RAPD- positive) enrolled the study. Three groups of masked examiners observed patients for an RAPD by swinging flashlight method (SFM) and O-Glass. The instrument captured and recorded eye pictures. The images were processed and analyzed using computerized software to calculate pupillary measurements. The results were compared between two methods and three different groups of examiners. Twenty six patients were known cases of multiple sclerosis related optic neuritis, fourteen of them had glaucoma and four patients had history of traumatic optic neuropathy. The mean age (SD) of the study participants (18 female and 26 male) was 35. All three groups of examiners were satisfactory with successful diagnosis by O-Glass. Conclusion: O-Glass is a simple eye-glass along with mobile friendly software that any care giver can use to perform the tests to identify a RAPD automatically and rapidly. The ability to store and archive the objective and quantifiable results for referencing and follow-ups, makes the device more valuable.

NCT ID: NCT02512133 Active, not recruiting - Glaucoma Clinical Trials

MIGS VS SLT Comparison in Glaucoma Patients

Start date: February 2012
Phase: Phase 3
Study type: Interventional

To compare the intraocular pressure (IOP) and number of glaucoma medications lowering of microinvasive glaucoma surgery (MIGS) with the implantation of the trabecular device Hydrus (Ivantis) as a solo procedure and 360° selective laser trabeculoplasty (SLT) to treat primary open angle glaucoma (POAG).

NCT ID: NCT02394613 Active, not recruiting - Glaucoma Clinical Trials

A Phase I Clinical Trial of DARC

Start date: May 2015
Phase: Phase 1
Study type: Interventional

Glaucoma is a major cause of irreversible blindness worldwide, caused by retinal nerve cell (RGC) death. This is currently identified only after significant vision loss has already occurred with an early event in, and a potential marker of, this process being RGC "apoptosis" (a form of cell death). This study aims to investigate the tolerability and safety of ANX776, as part of the new Detection of Apoptosing Retinal Cells (DARC) technique. This has been developed by the laboratory of DARC IP holder and grant applicant: Prof. M. Francesca Cordeiro. A secondary aim is to initially establish the ability of DARC to identify RGC apoptosis in the diagnosis of glaucoma in healthy and progressive glaucoma/glaucoma-suspect/ocular hypertensive patients. As a positive control for this secondary aim of this study, patients with Non-arteritic Anterior Ischaemic Optic Neuropathy (NAION) will be recruited. During the study, each patient will undergo several ophthalmological examinations, imaging of the back of the eye using established clinical devices, and blood sampling for studying the safety and toxicology profile of ANX776. The understanding of the safety profile of ANX776 is crucial for the use of DARC in patients, and its application as a potentially powerful new clinical tool with which to identify patients with early glaucoma before their vision is lost. If successful, it opens the door to directly observing effects of glaucoma treatments, including the assessment of new, breakthrough therapies.